Ublituximab in children, Vidofludimus Calcium in progression, Glatirameracetat in PPMS? All three were a topic at the ACTRIMS Congress in February 2026. Prof. Mathias Mäurer talks about the three active substances in this video. And
Continue reading
BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go
Continue reading
Tolebrutinib belongs to the class of Bruton tyrosine kinase inhibitors. Recently, negative news weakened hope for the BTKi, particularly among people with progressive multiple sclerosis. Professor Mathias Mäurer summarizes new information on Tolebrutinib in the
Continue reading
First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back
Continue reading
The year 2025 was not an easy year. It was characterized by intense political, economic and social developments. The war in Ukraine, the Gaza crisis, geopolitical tensions, but also domestic political disputes kept us on
Continue reading
On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1
Continue reading
Women of childbearing age are, compared to men, underrepresented in MS therapy. This was shown by a recent study. There is a gender gap in the use of immunomodulatory therapies (DMT). However, this does not
Continue reading
As already stated in the previous article “News from ECTRIMS (1)“: We have now become very good at controlling focal inflammation in MS – that is, the inflammatory response triggered by the influx of peripheral
Continue reading
Those who have been with DocBlog for a while know: autumn is congress time. As always at this time, the world’s largest MS meeting took place again this year – almost 10,000 MS experts from
Continue reading
There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
